Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer-Reference-Cited by-同舟云学术

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Published:2022-02-07 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Tapia-Galisteo Antonio¹^ORCID,Sánchez Rodríguez Íñigo¹^ORCID,Aguilar-Sopeña Oscar²³^ORCID,Harwood Seandean Lykke⁴^ORCID,Narbona Javier⁵,Ferreras Gutierrez Mariola⁶^ORCID,Navarro Rocío⁷^ORCID,Martín-García Laura¹,Corbacho Cesáreo⁸^ORCID,Compte Marta⁷^ORCID,Lacadena Javier⁵^ORCID,Blanco Francisco J.⁶^ORCID,Chames Patrick⁹^ORCID,Roda-Navarro Pedro²³^ORCID,Álvarez-Vallina Luis¹⁰¹¹^ORCID,Sanz Laura¹^ORCID

Affiliation:

1. Molecular Immunology Unit, Biomedical Research Institute Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

2. Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense de Madrid, Spain

3. Lymphocyte Immunobiology Group, Biomedical Research Institute Hospital 12 de Octubre, Madrid, Spain

4. Protein Science, Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark

5. Department of Biochemistry and Molecular Biology, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, Spain

6. Biomolecular NMR, Centro de Investigaciones Biológicas Margarita Salas-CSIC, Madrid, Spain

7. Department of Antibody Engineering, Leadartis Sl, Madrid, Spain

8. Pathology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

9. Antibody Therapeutics and Immunotargeting Group, Aix Marseille University, CNRS, INSERM, Institute Paoli-Calmettes, CRCM, Marseille, France

10. Cancer Immunotherapy Unit (UNICA), Hospital Universitario 12 de Octubre, Madrid, Spain

11. Immuno-oncology and Immunotherapy Group, Biomedical Research Institute Hospital 12 de Octubre, Madrid, Spain

Funder

Instituto de Salud Carlos III

Spanish Association Against Cancer

CRIS Cancer Foundation

predoctoral fellowship from Comunidad Autónoma de Madrid

Spanish Ministry of Science and Innovation

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2034355

Reference50 articles.

1. Bispecific antibodies

2. FDA Approval: Blinatumomab

3. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

4. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

5. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific T-Cell Engagers (BiTEs) in Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

2. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance;International Journal of Molecular Sciences;2024-06-28

3. Contemporary Approaches to Immunotherapy of Solid Tumors;Cancers;2024-06-19

4. Facile Access to Branched Multispecific Proteins;Bioconjugate Chemistry;2024-06-16

5. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31